TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINFα-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINFα-2a and Ribavirin Therapy (ATTAIN)

March 24, 2016 updated by: Janssen R&D Ireland

Phase III in Partial and Null Responders

The purpose of this study is to demonstrate the efficacy of TMC435 in combination with peginterferon (PegIFN) + ribavirin (RBV) by means of establishing its non- inferiority compared to an approved regimen of telaprevir + PegIFN + RBV in patients who have previously failed PegIFN.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This study is a randomized (study drug assigned by chance like flipping a coin), double-blind (neither physician nor patient knows the name of the assigned drug), double-dummy (patients receive both active and inactive pills also called placebo), 2-arm, multicenter Phase III clinical study in adult treatment experienced Chronic Hepatitis C (CHC) genotype-1 infected patients who failed to respond during at least 1 previous course of PegINFα-2a/ RBV therapy. The purpose of the trial is to study the efficacy of TMC435 in combination with PegINFα-2a and RBV for 48 weeks of treatment compared to the approved regimen of telaprevir in combination with PegINFα-2a and RBV for 48 weeks of treatment. The study will consist of a screening period (maximum 6 weeks), treatment period (48 weeks) and post-treatment period (until 72 weeks after the start of treatment). For the first 12 weeks one group of patients will take TMC435 and TVR placebo, plus PegINFα-2a and RBV. The other group will take TMC435 placebo and TVR, plus PegINFα-2a and RBV. After 12 weeks, patients in both arms will only take PegINFα-2a and RBV up to week 48. After patients stop taking study medication, they will continue to go to the doctor's office for study visits until a total of 72 weeks after they start study treatment. Patients will be monitored for safety throughout the study. Study assessments at each study visit may include, but are not limited to: blood and urine collection for testing, electrocardiogram (ECG) assessments (a measurement of the electrical activity of your heart), patient questionnaires, and physical examinations.

Study Type

Interventional

Enrollment (Actual)

771

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Buenos Aires, Argentina
      • Buenos Aires N/A, Argentina
      • Rosario, Santa Fe, Argentina
  • Australia
      • Darlinghurst, Australia
      • Greenslopes, Australia
      • Kingswood, Australia
      • Melbourne, Australia
      • Parkville - Vic, Australia
      • Perth, Australia
      • Sydney, Australia
      • Woolloongabba N/A, Australia
  • Austria
      • Linz, Austria
      • Wien, Austria
  • Belgium
      • Brussel, Belgium
      • Brussels, Belgium
      • Haine-Saint-Paul, La Louviere, Belgium
      • Leuven, Belgium
      • Liège, Belgium
  • Brazil
      • Campinas, Brazil
      • Ribeirão Preto, Brazil
      • Salvador, Brazil
      • Sao Paulo, Brazil
  • Bulgaria
      • Sofia, Bulgaria
      • Varna, Bulgaria
  • Canada
    • Alberta
      • Calgary, Alberta, Canada
      • Edmonton, Alberta, Canada
    • British Columbia
      • Vancouver, British Columbia, Canada
    • Ontario
      • Toronto, Ontario, Canada
    • Quebec
      • Montreal, Quebec, Canada
  • Czech Republic
      • Brno, Czech Republic
      • Karlovy Vary, Czech Republic
      • Plzen, Czech Republic
      • Praha 2, Czech Republic
      • Praha 4, Czech Republic
  • Denmark
      • Copenhagen, Denmark
      • Hvidovre N/A, Denmark
      • Odense N/A, Denmark
  • France
      • Grenoble, France
      • Lyon, France
      • Marseille, France
      • Nice, France
      • Paris, France
      • Paris Cedex 12, France
      • Pessac, France
      • Vandoeuvre Les Nancy, France
  • Germany
      • Berlin, Germany
      • Frankfurt N/A, Germany
      • Freiburg, Germany
      • Hamburg, Germany
      • Hannover, Germany
      • Heidelberg, Germany
      • Kiel, Germany
      • Mainz, Germany
      • München, Germany
      • Stuttgart, Germany
      • Ulm, Germany
      • Würzburg, Germany
  • Greece
      • Alexandroupolis, Greece
      • Athens, Greece
      • Larissa, Greece
  • Hungary
      • Budapest, Hungary
      • Debrecen, Hungary
      • Kaposvár, Hungary
      • Pecs, Hungary
      • Szeged N/A, Hungary
  • Israel
      • Haifa, Israel
      • Jerusalem, Israel
      • Petah Tiqva, Israel
      • Ramat-Gan, Israel
      • Tel-Aviv, Israel
      • Zefat, Israel
  • Norway
      • Fredrikstad, Norway
      • Nordbyhagen, Norway
      • Stavanger, Norway
      • Tromsø, Norway
  • Poland
      • Bydgoszcz, Poland
      • Chorzow, Poland
      • Kielce, Poland
      • Lodz, Poland
      • Lublin, Poland
      • Myslowice, Poland
      • Raciborz, Poland
      • Warszawa, Poland
  • Portugal
      • Lisboa, Portugal
      • Lisbon, Portugal
      • Porto, Portugal
  • Puerto Rico
      • Santurce, Puerto Rico
  • Romania
      • Bucuresti, Romania
      • Constanta, Romania
      • Iasi, Romania
      • Timisoara, Romania
  • Spain
      • Barcelona, Spain
      • Madrid, Spain
      • Santander N/A, Spain
      • Sevilla N/A, Spain
      • Valencia, Spain
  • Sweden
      • Göteborg, Sweden
      • Lund, Sweden
      • Malmö, Sweden
      • Stockholm, Sweden
      • Örebro, Sweden
  • Switzerland
      • Lugano, Switzerland
      • St Gallen, Switzerland
      • Zurich N/A, Switzerland
  • United Kingdom
      • Glasgow, United Kingdom
      • Leeds, United Kingdom
      • London, United Kingdom
      • Newcastle Upon Tyne, United Kingdom
      • Plymouth, United Kingdom
      • Southampton, United Kingdom
  • United States
    • California
      • Bakersfield, California, United States
      • San Diego, California, United States
    • Colorado
      • Aurora, Colorado, United States
    • District of Columbia
      • Washington, District of Columbia, United States
    • Florida
      • Jacksonville, Florida, United States
      • Orlando, Florida, United States
      • West Palm Beach, Florida, United States
    • Georgia
      • Atlanta, Georgia, United States
    • Hawaii
      • Honolulu, Hawaii, United States
    • Illinois
      • Chicago, Illinois, United States
    • Kentucky
      • Crestview Hills, Kentucky, United States
    • Louisiana
      • New Orleans, Louisiana, United States
    • Maryland
      • Chevy Chase, Maryland, United States
    • Mississippi
      • Jackson, Mississippi, United States
      • Tupelo, Mississippi, United States
    • Missouri
      • Kansas City, Missouri, United States
    • Montana
      • Missoula, Montana, United States
    • New Jersey
      • Newark, New Jersey, United States
    • New York
      • New York, New York, United States
      • Rochester, New York, United States
    • Ohio
      • Cincinnati, Ohio, United States
      • Cleveland, Ohio, United States
    • Pennsylvania
      • Allentown, Pennsylvania, United States
      • Philadelphia, Pennsylvania, United States
      • Pittsburgh, Pennsylvania, United States
    • Texas
      • Arlington, Texas, United States
      • Houston, Texas, United States
      • Odessa, Texas, United States
      • San Antonio, Texas, United States
    • Virginia
      • Falls Church, Virginia, United States
    • Washington
      • Bellevue, Washington, United States
      • Seattle, Washington, United States

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patient must have had a liver biopsy before screening (or between the screening and baseline visit), unless patient cannot undergo such a procedure or has evidence of portal hypertension not associated with cirrhosis. For patients who had a liver biopsy performed more than 2 years prior to screening or without a biopsy (because of a contraindication or portal hypertension), a non-invasive staging assessment needs to be available. Non-invasive staging assessments include FibroScan, MR-Elastography, or FibroTest/FibroSure and must not be older than 6 months prior to screening
  • Chronicity of hepatitis C virus (HCV) infection, as confirmed by one or both of the following: presence of anti-HCV antibody and/or HCV ribonucleic acid (RNA) at least 6 months prior to the screening visit and/or presence of fibrosis on biopsy
  • Genotype 1 HCV infection with plasma HCV RNA of >10,000 IU/mL (both confirmed at screening)
  • Patient must have had at least 1 documented previous course of treatment with PegINFα-2a or PegINFα-2b in combination with ribavirin (RBV) (at least 12 weeks for null responder and 20 weeks for partial responder)

Exclusion Criteria:

  • Hepatic decompensation (impaired functioning of the liver), as indicated by significant laboratory abnormalities or other active diseases
  • Infection with Human Immunodeficiency Virus (HIV) or non genotype 1 hepatitis C
  • Liver disease not related to hepatitis C infection
  • Previous chronic hepatitis C treatment, other than PegIFN and RBV

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TMC435/PR
Drug: TMC435
TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
Active Comparator: TVR/PR
Drug: TVR
TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants With Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)
Time Frame: 12 Weeks After the Planned End of Treatment (EOT: Week 48)
Participants are considered to have reached SVR12 if both conditions below are met: 1) HCV RNA levels less than (<) 25 International unit per milliliter (IU/mL) undetectable; 2) HCV RNA levels <25 IU/mL undetectable or HCV RNA levels <25 IU/mL detectable.
12 Weeks After the Planned End of Treatment (EOT: Week 48)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants With Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)
Time Frame: 24 Weeks After the Planned EOT (Week 48)
Participants are considered to have reached SVR24 if both conditions below are met: 1) HCV RNA levels less than <25 International unit per milliliter (IU/mL) undetectable (at the actual end of treatment);2) HCV RNA levels <25 IU/mL undetectable or HCV RNA levels <25 IU/mL detectable (24 weeks after the planned EOT).
24 Weeks After the Planned EOT (Week 48)
Percentage of Participants With Viral Relapse
Time Frame: End of Treatment (Week 48) up to Follow-up Period (until Week 72)
Participants are considered to have a viral relapse if both conditions as specified are met: 1) <25 IU/mL undetectable HCV RNA at the actual end of study drug treatment; 2) confirmed HCV RNA greater than or equal to (>=) 25 IU/mL during follow-up.
End of Treatment (Week 48) up to Follow-up Period (until Week 72)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Janssen R&D Ireland

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2012

Primary Completion (Actual)

April 1, 2014

Study Completion (Actual)

April 1, 2014

Study Registration Dates

First Submitted

November 25, 2011

First Submitted That Met QC Criteria

December 2, 2011

First Posted (Estimate)

December 6, 2011

Study Record Updates

Last Update Posted (Estimate)

April 26, 2016

Last Update Submitted That Met QC Criteria

March 24, 2016

Last Verified

March 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CR100677
  • TMC435HPC3001 (Other Identifier: Janssen R&D Ireland)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hepatitis C

Clinical Trials on TMC435

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe